Listen: HHS Files Challenge Over Rights To Gilead’s HIV-Prevention Drug
KHN's Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
Drug Costs
321-340 of 711 results
-
-
Analysis: Elizabeth Warren Throws Down The Gauntlet
She has led the way, but all the candidates need to come clean about their health care proposals.
-
FDA Keeps Brand-Name Drugs On A Fast Path To Market ― Despite Manufacturing Concerns
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors.
-
Moved Overseas For School, Stayed For Insulin
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
-
Pharma Sells States On ‘Netflix Model’ To Wipe Out Hep C. But At What Price?
Manufacturers of lucrative drugs say they’re offering discounts off the high sticker prices ― but taxpayers footing the big bills might never know what the state is paying or if it’s getting a good deal.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
-
KHN’s ‘What The Health?’: Democrats Do Drugs (Prices)
House Democrats start legislative work on House Speaker Nancy Pelosi’s prescription drug pricing bill; health is again a featured player in the Democratic presidential candidate debate; and courts around the country hold up President Donald Trump’s health agenda. This week, Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
-
California Governor’s Bill-Signing Marathon Offers Glimpse Of 2020 Issues
California Gov. Gavin Newsom signed off on an array of health care bills that will significantly affect the lives of Californians, including many college students, pregnant women, schoolchildren and dialysis patients.
-
California’s New Transparency Law Reveals Steep Rise In Wholesale Drug Prices
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California’s first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
As Medicare Enrollment Nears, Popular Price Comparison Tool Is Missing
For more than a decade, customers used the online plan finder to compare dozens of policies. Yet after a redesign of the website, the search results no longer list which plan offers a customer the best value. Federal officials say it will be fixed before enrollment begins next week.
By Susan Jaffe -
KHN’s ‘What The Health?’: Impeachment And The Health Agenda
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
-
As Off-Label Use Spreads, Supplies Of Niche Drugs And Patients’ Patience Grow Short
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication’s long production window.
-
Hill Hodgepodge: Pelosi Draws From Democrats, GOP And Trump For Drug Plan
The House speaker announced her plan for lowering drug prices, which includes negotiations between drugmakers and federal health officials.
-
KHN’s ‘What The Health?’: Tennessee Seeks Medicaid Changes
Tennessee wants to convert its Medicaid program to a block grant. But is its plan legal? Meanwhile, Congress continues to struggle with legislation to rein in prescription drug prices and surprise medical bills. This week, Anna Edney of Bloomberg News, Jennifer Haberkorn of the Los Angeles Times and Kimberly Leonard of the Washington Examiner join KHN’s Julie Rovner to discuss these issues and more. Rovner also interviews Dr. Marty Makary, author of the new book “The Price We Pay” about why health care costs so much.
-
Purveyors Of Black-Market Pharmaceuticals Target Immigrants
Illegal medications, sold in immigrant communities around the United States, can cause serious harm to consumers, authorities say. Law enforcement officers are cracking down, but some think more must be done.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHN’s ‘What The Health?’: Despite Booming Economy, Uninsured Rate Ticks Up
Nearly 2 million more Americans were uninsured in 2018 than in the previous year, according to the Census Bureau’s annual report. Plus, the Trump administration announced plans to ban flavored vape liquids, and Congress is back and working to address high prescription drug prices and “surprise” medical bills. This week, Joanne Kenen of Politico, Tami Luhby of CNN and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
-
Legislation To End Surprise Medical Bills Has High Public Support — In Both Parties
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
-
States Pass Record Number Of Laws To Reel In Drug Prices
So far this year, 33 states have enacted more than 50 measures to address drug prices, affordability and access. Congress is eyeing the efforts to see what works.